Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The type I interferon (IFN) receptor signaling pathway is a critical mechanism by which the immune system detects and responds to viral infections and other immune challenges. This pathway is initiated when type I interferons bind to their common cell surface receptor complex known as the type I interferon receptor (IFNAR), which consists of two subunits: IFNAR1 and IFNAR2. Upon binding of a type I interferon ligand, intracellular kinases JAK1 and TYK2 are activated, leading to phosphorylation of STATs and subsequent transcriptional activation of hundreds of interferon-stimulated genes (ISGs) that mediate antiviral defense, immunomodulation, apoptosis regulation, and anti-proliferative effects.
Activation of JAK-STAT signaling pathway leading to transcription of interferon-stimulated genes (ISGs).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immune system modulation via type I interferon receptor signaling pathway.